✦ LIBER ✦

PCN155 Patient Benefit-Risk Preferences for Advanced Renal Cell Carcinoma Treatments: Results From a Conjoint Analysis Study

✍ Scribed by Mohamed, A.; Yang, J.C.; Hauber, A.B.; Liu, Z.; Wong, M.; Rogerio, J.; Garay, C.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN110 HOW MUCH DO PATIENTS WITH RENAL C

✍ AB Hauber; AF Mohamed; FR Johnson; MP Neary 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

Patient And Physician Preferences In The

✍ Levitan, B.; Yuan, Z.; González, J.M.; Hauber, A.B.; Lees, M.; Piccini, J.P.; Si 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN50 COSTS OF TREATMENT WITH ANGIOGENES

✍ WK Oh; DF McDermott; MS Duh; L Antràs; K Chen; SP Sarda; A Luka; S Whittemore; P 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Axitinib versus sorafenib as second-line

✍ Motzer, Robert J; Escudier, Bernard; Tomczak, Piotr; Hutson, Thomas E; Michaelso 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 316 KB

Reply from Authors re: Simon P. Kim, R.

✍ Maxine Sun; Firas Abdollah; Marco Bianchi; Pierre I. Karakiewicz 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 51 KB

7136 POSTER The Association Between Trea

✍ Oudard, S.; Porta, C.; Castellano, D.; McDermott, R.; Nathan, P.; McCaffrey, J.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 60 KB